Drug
Vatreptacog alfa clinical trials
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2007 (1)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2009 | 1 |
| 2011 | 1 |
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses vatreptacog alfa is read from its arms, and is right about nine times in ten.
Testing it · 3
- Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and InhibitorsCompletedPhase 3Novo Nordisk A/SNCT01392547Written as vatreptacog alfa (activated)
- Haemophilia Patients With Inhibitors Being Treated for Acute Joint BleedsCompletedPhase 2Novo Nordisk A/SNCT00486278Written as vatreptacog alfa (activated)
- Safety, Tolerability and Pharmacokinetics of NN1731 in Healthy VolunteersCompletedPhase 1Novo Nordisk A/SNCT00822185Written as vatreptacog alfa (activated)
Codes
What other systems call vatreptacog alfa · ClinicalTrials.gg INT000197
- MeSH (NLM) C000596433vatreptacog alfaOne source NLM
- UNII (FDA) 2F6ZF5WYCCVATREPTACOG ALFAConfirmed FDA, NLM
- NCI Thesaurus C152841Vatreptacog AlfaOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000596433 | vatreptacog alfa | One source NLM |
| UNII (FDA) | 2F6ZF5WYCC | VATREPTACOG ALFA | Confirmed FDA, NLM |
| NCI Thesaurus | C152841 | Vatreptacog Alfa | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.